Clinical advances in later-line therapy for metastatic or refractory colorectal cancer

Table 3 Aflibercept-based treatment strategies

Trial name/Ref.	Regimen	Sample size	Dosage and administration (experimental group)	mPFS (months, 95%CI)	Hazard ratio (95%CI); P value	mOS (months, 95%CI)	Hazard ratio (95%CI); P value	ORR (%); P value
Beom et al[61], 2023	Aflibercept + FOLFIRI	185	Aflibercept: 4 mg/kg q2w; FOLFIRI1	7.3		9.4		14.60%
HGCSG1801[62], 2024	Aflibercept + FOLFIRI	43	Aflibercept: 4 mg/kg q2w; irinotecan: 180 mg/m2 q2w; leucovorin: 200 mg/m2 q2w; 5-FU: 400 mg/m2 and 2400 mg/m2 (46 hours) q2w	7.3 (5.5–11.0)		18.8 (12.9–26.6)		20.90%
Martínez-Lago et al[63], 2022	Aflibercept + FOLFIRI	75	Aflibercept: 4 mg/kg q2w; irinotecan: 180 mg/m2 q2w; leucovorin: 400 mg/m2 q2w; 5-FU: 400 mg/m2 and 2400 mg/m2 (46 hours) q2w	6.6 (5.3–7.9)		15.1 (12.5–17.8)		33.80%
Claramunt García et al[66], 2022	Bevacizumab + FOLFIRI vs aflibercept + FOLFIRI	84		9.9 (7.5–12.2) vs 4.7 (3.6–5.7)	0.67 (0.39–1.12); P = 0.159	16.2 (13.3–19.1) vs 9.3 (5.3–13.4)	0.57 (0.34–0.94); P = 0.026

¹Not reported.

5-FU: 5-Fluorouracil; CI: Confidence interval; mOS: Median overall survival; mPFS: Median progression-free survival; ORR: Objective response rate.